1-(2-丁基)哌嗪 | 34581-21-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(2-丁基)哌嗪
• 英文名称: N-(sec.-butyl)-piperazine
• 英文别名: 1-(sec-butyl)piperazine；1-sec-butylpiperazine；1-sec-butyl-piperazine；4-(sec-butyl)piperazine；1-sec-butyl-piperazine；1-(2-Butyl)piperazine；1-butan-2-ylpiperazine
• CAS: 34581-21-0
• 化学式: C₈H₁₈N₂
• 分子量: 142.244
• InChiKey: ZHHCLIRTNOSAPB-UHFFFAOYSA-N

物化性质

• 沸点：
  189.6±8.0 °C(Predicted)
• 密度：
  0.877±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  1-(2-丁基)哌嗪 在 草酰氯 、 potassium carbonate 、 三乙胺 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 (4-sec-Butyl-piperazin-1-yl)-(4-hydroxy-phenyl)-methanone
  参考文献：
  名称：

  Synthesis of 4-(4-guanidinobenzoyloxy)benzamides and 1-(4-guanidinobenzoyloxy)benzoyloxy acetamides as trypsin inhibitors

  摘要：

  Seventeen new compounds of 4-(4-guanidinobenzoyloxy)benzamides and 4-(4-guanidinobenzoyloxy)benzoyloxyacetamides were prepared and their inhibitory activities on trypsin, thrombin and porcine pancreatic elastase were measured. These compounds were found to be selective trypsin inhibitors with inhibiting activities from 0.44 to 43 mu M.

  DOI：

  10.1016/s0223-5234(97)89852-2
• 作为产物：
  描述：

  1-(4-sec-Butyl-piperazin-1-yl)-2,2,2-trifluoro-ethanone 在 potassium carbonate 作用下， 以 甲醇 、 水 为溶剂， 反应 20.0h， 生成 1-(2-丁基)哌嗪
  参考文献：
  名称：

  Kawaguchi, Mamoru; Hayashi, Osamu; Kanamoto, Masahiro, Agricultural and Biological Chemistry, 1987, vol. 51, # 2, p. 435 - 440

  摘要：

  DOI：

文献信息

• PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF
  申请人：Ancureall Pharmaceutical (Shanghai) Co., Ltd.

  公开号：US20210101881A1

  公开（公告）日：2021-04-08

  The present invention discloses a pyrimidine compound, a preparation method thereof and a medical use thereof. Specifically, the present invention discloses a pyrimidine compound represented by formula (I), pharmaceutically acceptable salts thereof, a preparation method thereof, and a use thereof as a cyclin-dependent kinase 9 (CDK9) inhibitor, particularly for the treatment of cancer. The definition of each group in formula (I) is the same as that in the specification.

  本发明公开了一种嘧啶化合物，其制备方法及医药用途。具体地，本发明公开了一种由式(I)表示的嘧啶化合物，其药学上可接受的盐，其制备方法，以及作为细胞周期依赖性激酶9（CDK9）抑制剂的用途，特别用于癌症治疗。式(I)中每个基团的定义与规范中的相同。
• IMIDAZO PYRIDINE DERIVATIVES
  申请人：Taracido Ivan Cornella

  公开号：US20090291942A1

  公开（公告）日：2009-11-26

  The invention relates to novel imidazopyridine derivatives and to their use in the treatment of diseases and disorders which may e.g. involve angiogenesis and/or pain, including autoimmune and inflammatory diseases.

  这项发明涉及新型咪唑吡啶衍生物及其在治疗可能涉及血管生成和/或疼痛的疾病和紊乱中的应用，包括自身免疫和炎症性疾病。
• Process for Isomerization of CIS-2-Pentenenitrile to 3-Pentenenitriles
  申请人：BASF SE

  公开号：US20130289299A1

  公开（公告）日：2013-10-31

  The present invention relates to an improved process for batchwise or continuous isomerization of cis-2-pentenenitrile to 3-pentenenitriles in the presence of 1,4-diazabicyclo[2.2.2]octane as catalyst.

  本发明涉及在1,4-二氮杂双环[2.2.2]辛烷存在下，对顺-2-戊烯腈进行批量或连续异构化改进过程，以得到3-戊烯腈。
• THERAPEUTIC ISOXAZOLE COMPOUNDS
  申请人：Kaplan Alan P.

  公开号：US20090062252A1

  公开（公告）日：2009-03-05

  The invention provides a compound of formula I: wherein A 1 , A 2 , A 3 , R 1 , X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of monoamine oxidase B (MAO-B) enzyme function and are useful for improving cognitive function and for treating psychiatric disorders in animals.

  该发明提供了一种式I的化合物：其中A1、A2、A3、R1、X、Y和B具有本文所描述的任何值，以及这些化合物的盐、包含这些化合物的组合物，以及包括给予这些化合物的治疗方法。这些化合物是单胺氧化酶B（MAO-B）酶功能的抑制剂，对于改善认知功能和治疗动物的精神障碍非常有用。
• Cyclohexyl piperazinyl methanone derivatives
  申请人：Nettekoven Matthias

  公开号：US20070167436A1

  公开（公告）日：2007-07-19

  The present invention relates to compounds of formula I wherein s, R 1a and R 1 to R 3 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

  本发明涉及公式I的化合物，其中s，R1a和R1到R3如描述和索赔中定义，并且其药学上可接受的盐。这些化合物可用于治疗和/或预防与H3受体调节相关的疾病。